Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 394

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

Open access
Lefebvre, Celine, Bachelot, Thomas, Filleron, Thomas, Pedrero, Marion, Campone, Mario, Soria, Jean-Charles, Massard, Christophe, Lévy, Christelle, Arnedos, Monica, Lacroix-Triki, Magali, Garrabey, Julie, Boursin, Yannick, Deloger, Marc, Fu, Yu, Commo, Frédéric, Scott, Véronique, Lacroix, Ludovic, Dieci, Maria Vittoria, Kamal, Maud, Diéras, Véronique, Gonçalves, Anthony, Ferrerro, Jean-Marc, Romieu, Gilles, Vanlemmens, Laurence, Mouret Reynier, Marie-Ange, Théry, Jean-Christophe, Le Du, Fanny, Guiu, Séverine, Dalenc, Florence, Clapisson, Gilles, Bonnefoi, Hervé, Jimenez, Marta, Le Tourneau, Christophe, André, Fabrice · 2016 · PLOS Medicine

Abstract

BACKGROUND: Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing. METHODS AND FINDINGS: Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trials. Mutational profiles from 772 primary breast tumors from The Cancer Genome Atlas (TCGA) were used as a reference for comparing primary and mBC mutational profiles. Twelve genes (TP53, PIK3CA, GATA3, ESR1, MAP3K1, CDH1, AKT1, MAP2K4, RB1, PTEN, CBFB, and CDKN2A) were identified as significantly mutated in mBC (false discovery rate [FDR] < 0.1). Eight genes (ESR1, FSIP2, FRAS1, OSBPL3, EDC4, PALB2, IGFN1, and AGRN) were more frequently mutated in mBC as compared to eBC (FDR < 0.01). ESR1 was identified both as a driver and as a metastatic gene (n = 22, odds ratio = 29, 95% CI [9-155], p = 1.2e-12) and also presented with focal amplification (n = 9) for a total of 31 mBCs with either ESR1 mutation or amplification, including 27 hormone receptor positive (HR+) and HER2 negative (HER2-) mBCs (19%). HR+/HER2- mBC presented a high prevalence of mutations on genes located on the mechanistic target of rapamycin (mTOR) pathway (TSC1 and TSC2) as compared to HR+/HER2- eBC (respectively 6% and 0.7%, p = 0.0004). Other actionable genes were more frequently mutated in HR+ mBC, including ERBB4 (n = 8), NOTCH3 (n = 7), and ALK (n = 7). Analysis of mutational signatures revealed a significant increase in APOBEC-mediated mutagenesis in HR+/HER2- metastatic tumors as compared to primary TCGA samples (p < 2e-16). The main limitations of this study include the absence of bone metastases and the size of the cohort, which might not have allowed the identification of rare mutations and their effect on survival. CONCLUSIONS: This work reports the results of the analysis of the first large-scale study on mutation profiles of mBC. This study revealed genomic alterations and mutational signatures involved in the resistance to therapies, including actionable mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002201

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 394

Metadata

Authors
Lefebvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J.-C., Massard, C., Lévy, C., Arnedos, M., Lacroix-Triki, M., Garrabey, J., Boursin, Y., Deloger, M., Fu, Y., Commo, F., Scott, V., Lacroix, L., Dieci, M. V., Kamal, M., Diéras, V., Gonçalves, A., Ferrerro, J.-M., Romieu, G., Vanlemmens, L., Mouret Reynier, M.-A., Théry, J.-C., Le Du, F., Guiu, S., Dalenc, F., Clapisson, G., Bonnefoi, H., Jimenez, M., Le Tourneau, C., & André, F.
Venue
PLOS Medicine
Published
2016-12-27
Volume
13
Issue
12
Pages
e1002201
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2570752636
Cited by
394
References
36
FWCI
13.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. https://app.cochat.ai/papers/10.1371/journal.pmed.1002201
The paper
Lefebvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J.-C., Massard, C., Lévy, C., Arnedos, M., Lacroix-Triki, M., Garrabey, J., Boursin, Y., Deloger, M., Fu, Y., Commo, F., Scott, V., Lacroix, L., Dieci, M. V., Kamal, M., . . . André, F. (2016). Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002201

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.